Loading
FH
Future Health ESG Corp. Stock: price and insider trades · United States
Future Health ESG Corp.: what insiders have been doing
Future Health ESG Corp. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Future Health ESG Corp. has published a filing in the past twelve months. The most recent one dates from 14 February 2025.
The full history, which starts in 2021, counts no purchases against 13 sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
30
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€34,656
13 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Net income-US$41.7k
Last declaration on 14 February 2025
Declarations30 total
798,745 shares@ US$11.0699.8% of flowCommon stock, par value $0.0001 per shareSEC:0001326389-25-000101:0
1,255 shares@ US$11.910.2% of flowCommon stock, par value $0.0001 per shareSEC:0001326389-24-000126:0
295,602 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048024:1
12,203 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048024:2
67,954 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048024:3
295,602 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048023:1
12,203 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048023:2
67,954 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048023:3
1,703,486 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048024:0
1,703,486 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048025:0
1,703,486 sharesCommon stock, par value $0.0001 per shareSEC:0001104659-24-048023:0
73,406 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129984:1
337 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129984:2
16,893 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129984:3
5,631 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129990:1
1,689 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129991:1
5,631 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129989:1
73,406 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129987:1
1,485 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129987:2
44,042 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129987:3
93,750 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129984:0
393,750 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129982:0
187,500 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129992:0
1,688 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129990:0
1,688 shares0Common stock, par value $0.0001 per shareSEC:0001104659-21-129989:0
25 of 30 declarations
About Future Health ESG Corp.
Future Health ESG Corp. (ticker: FHLT) is a United States-listed company on the NASDAQ market, with its principal executive office historically disclosed in Dover, Delaware, United States. The company was originally formed in February 2021 as a SPAC, meaning a blank-check acquisition vehicle created to pursue a merger, stock exchange, asset purchase, reorganization, or similar business combination with one or more operating businesses. SEC filings show that, before completing an initial business combination, Future Health ESG Corp. had no traditional operating business of its own. Its original investment thesis was focused on healthcare, specifically scale-up-stage healthcare companies that use modern technology and data science to improve outcomes, reduce waste, and better personalize care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1851182/000141057823002421/fhltu-20230930x10q.htm?utm_source=openai))
From an investor’s perspective, FHLT should be analyzed differently from a conventional healthcare manufacturer, diagnostics company, or pharmaceutical group. Historically, it functioned as a public-market acquisition vehicle rather than an operating company with an established product portfolio. Its business model prior to a transaction was centered on holding IPO proceeds in trust, earning interest income, and searching for a suitable target. The company’s listed securities included common stock, units, and warrants on Nasdaq, reflecting the standard SPAC capital structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1851182/000141057823002421/fhltu-20230930x10q.htm?utm_source=openai))
Read moreShow less
In competitive terms, Future Health ESG Corp. operated in the highly crowded SPAC universe, where execution risk is high and equity value depends primarily on sourcing and closing an attractive healthcare target, securing shareholder approval, and maintaining the public listing. In June 2022, Nasdaq-related disclosure highlighted that Future Health had announced a proposed business combination with Excelera DCE, underscoring the company’s intent to transition from a shell vehicle into a healthcare-focused operating platform. For market participants, the key questions are therefore deal completion, post-transaction integration, and whether the target business can create durable growth after the combination. ([nasdaq.com](https://www.nasdaq.com/press-release/excelera-to-become-publicly-traded-via-merger-with-future-health-nasdaq%3A-fhlt-2022-06?utm_source=openai))
Geographically, the company’s footprint has been predominantly U.S.-based, with incorporation in Delaware and executive-office disclosure in Delaware. Based on the public record reviewed, there is no strong evidence of a broad international operating footprint comparable to a mature healthcare corporation. Recent notable items in the SEC record relate mainly to the proposed business combination, proxy materials, and Form 4 insider transaction filings, which collectively point to a company in transition rather than an established revenue-generating healthcare business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1851182/000110465922082471/fhltu-20211231xs4.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
